Halozyme Therapeutics (NASDAQ: HALO) stock: the official figures
Halozyme Therapeutics (HALOZYME THERAPEUTICS, INC.) is listed on Nasdaq under the ticker HALO and belongs to the health care sector. In fiscal 2025 it reported revenue of $1,397m and a net profit of $316.9m, according to the annual accounts it filed with the regulator.
Identifiers for Halozyme Therapeutics: SEC CIK 1159036.
Fiscal 2025 figures
| Item | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | $1,397m | $1,015m | +37.6% |
| Operating profit | $469.0m | $551.5m | −15.0% |
| Net profit | $316.9m | $444.1m | −28.6% |
| Earnings per share | $2.64 | $3.50 | −24.6% |
| Operating margin | 33.6% | 54.3% | −20.7 pts |
| Net margin | 22.7% | 43.7% | −21.0 pts |
| Total assets | $2,525m | $2,063m | +22.4% |
| Equity | $48.8m | $363.8m | −86.6% |
| Cash | $133.8m | $115.9m | +15.5% |
| Operating cash flow | $651.6m | $479.1m | +36.0% |
Margins are calculated from the filed figures: operating profit and net profit over revenue.
10 fiscal years
| Fiscal year | Revenue | Operating profit | Net profit | Earnings per share | Document |
|---|---|---|---|---|---|
| 2025 | $1,397m | $469.0m | $316.9m | $2.64 | Annual report |
| 2024 | $1,015m | $551.5m | $444.1m | $3.50 | Annual report |
| 2023 | $829.3m | $337.6m | $281.6m | $2.13 | Annual report |
| 2022 | $660.1m | $267.5m | $202.1m | $1.48 | Annual report |
| 2021 | $443.3m | $275.9m | $402.7m | $2.86 | Annual report |
| 2020 | $267.6m | $144.3m | $129.1m | $0.95 | Annual report |
| 2019 | $196.0m | −$67.6m | −$72.2m | −$0.50 | Annual report |
| 2018 | $151.9m | −$69.3m | −$80.3m | −$0.56 | Annual report |
| 2017 | $316.6m | $81.0m | $63.0m | $0.46 | Annual report |
| 2016 | $146.7m | −$83.2m | −$103.0m | −$0.81 | Annual report |
The full income statement, balance sheet and cash flow statement are in the annual accounts of Halozyme Therapeutics. Purchases and sales by its executives and directors are in insider transactions.
Members of Congress who traded Halozyme Therapeutics
In the congressional reports read up to 9 November 2026, 1 member has disclosed 3 transactions in Halozyme Therapeutics: Gilbert Ray Cisneros, Jr. (3).
Frequently asked questions about Halozyme Therapeutics
- How much did Halozyme Therapeutics earn in fiscal 2025?
- Halozyme Therapeutics reported a net profit of $316.9m for fiscal 2025, on revenue of $1,397m. The year before it reported a net profit of $444.1m.
- What are the earnings per share of Halozyme Therapeutics?
- They were $2.64 in fiscal 2025, compared with $3.50 the year before.
- Where is Halozyme Therapeutics listed?
- Halozyme Therapeutics is listed on Nasdaq under the ticker HALO and belongs to the health care sector.
- Where do the figures for Halozyme Therapeutics come from?
- From the annual report (Form 10-K) that Halozyme Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
The annual accounts come from the annual report (Form 10-K) that Halozyme Therapeutics files with the SEC, the US securities regulator. Each fiscal year in the table links to its filing. Celsmar reads the tagged figures from the document and does not adjust them: if an item is not in the filing, it is not shown. More detail in data sources and, if you spot an error, in corrections. What Celsmar is and what it costs, in its fact sheet.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.